PeerVoice Clinical Pharmacology Audio

Richard David Graham Leslie, MD, FRCP, FAoP - When Could Dysglycaemia in Adults Be Type 1 Diabetes? Expert Perspectives on Recognising and Addressing Diagnostic Complexities and Challenges

Maria Dall'Era, MD - When They Need Targeted Therapy: Selecting the Optimal Treatment Approach for Lupus Nephritis in an Evolving Treatment Landscape

Chloe E. Atreya, MD, PhD / Marwan Fakih, MD - Focusing on the Patient in Front of Us: Expert Perspectives on Providing Patient-Centered Care for Refractory Metastatic Colorectal Cancer

Dustin A. Deming, MD - Personalizing Treatment Pathways for Refractory Metastatic Colorectal Cancer: Informed Decision-Making When Disease Has Progressed

Mike Sharma, MD, MSc, FRCPC - Can We Set a New Standard of Care for Secondary Stroke Prevention? Evaluating Current Gaps and Future Goals

Enrico Lopriore, MD, PhD - Are You Managing Pregnant Individuals? Then You Need to Know About Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT)

Mariana Castells, MD, PhD - Rare But Highly Significant: Best Practices in Recognizing and Diagnosing Systemic Mastocytosis

Olivier Bonnot, MD, PhD - Acute Psychosis: When to Suspect Acute Hepatic Porphyria

Darren M. Brenner / Benoît Coffin - If I'd Known Then What I Know Now: Recognising My First AHP Patient

Dirk Arnold, MD, PhD - Still in the Game! Optimising Treatment Sequencing in the Management of Relapsed or Refractory mCRC

Olga Kordonouri, MD - Confronting the Silent Progression of Type 1 Diabetes: Rationales and Roadmaps for Early Detection and Proactive Intervention

Kris V. Kowdley, MD - Prioritising the Patient Experience With PBC: Are We Appreciating and Addressing the True Impact of the Disease?

Pushpa Narayanaswami, MD, FAAN - Cutting Through the Congress Cacophony on Generalised Myasthenia Gravis: Expert Honing of the Latest Data

Erika Hamilton, MD - Safety First: Recognising and Responding to Toxicities Associated With TROP2-Directed Therapies in Metastatic Breast Cancer

Onyema Ogbuagu, MD, FACP, FIDSA - Multidrug-Resistant HIV: Evaluating HIV Treatment Strategies as Options Narrow

Maurie Markman, MD - Testing Impacts Treatment: Applying Best Practices in HER2 Assessment in Solid Tumours

Harry Paul Erba, MD, PhD - New Tools, New Considerations: Optimizing Our Approaches to Managing Newly Diagnosed FLT3-Mutant AML

Ana Oaknin, MD, PhD - HER2 as an Actionable Target in Gynaecological Cancers: Implications of Therapeutic Advances on Clinical Practice

Neal Shore, MD, FAC - Advancing Care for mCRPC With Life-Prolonging Therapies: Existing and Emerging Roles for Radiopharmaceuticals

Angela Fitch, MD, FACP, MFOMA - This Cannot Weight: A Specialist Guide to Weight Management and Obesity Associated With Emotional Eating Behaviours

Bruce A C Cree, MD, PhD, MAS - BTK Inhibition & Beyond: Novel Therapies in MS

Elena Castro, MD, PhD - Innovation and Individualisation in mHSPC and nmCRPC: Optimising Patient Outcomes and Experiences

Karin Jordan, MD, PhD - Applying Foresight to Optimise Emesis Control in Patients Receiving Antibody-Drug Conjugates

Karin Jordan, MD, PhD - Practical Protocols for Preventing and Managing Antibody-Drug Conjugate-Associated Nausea and Vomiting

Deborah Siegal, MD, MSc, FRCPC / Richard Body, MBChB, FRCEM, PhD - Turn the Bleed Around: Expert Perspectives on the Evolving Evidence for Management of Factor Xa Inhibitor-Associated Life-Threatening Bleeding

Jiwon Oh, MD, PhD, FRCPC - Navigating the High-Efficacy DMT Landscape in MS: Integrating New Data and Real-World Evidence

Frank Siebenhaar, PD / Vito Sabato, MD, PhD - Optimising Outcomes in Indolent Systemic Mastocytosis: A Comprehensive Review of Best Practices Across the Patient Journey

Sharon Walmsley, MD - If the Drugs Are Working, Why Switch HIV Treatment in People Who Are Virologically Suppressed?

Jane Anderson, FRCP, PhD - Health-Related Quality of Life: What Works Best for People Living With HIV?

Jacqueline S. Garcia, MD - Small Words, Big Differences: Best Practices in Supportive Care for Patients With AML

Jai Radhakrishnan, MD, MS, Getting Up to Speed in IgAN: An Expert-Led Rapid-Fire Journal Club Series

Philippe Moreau, MD - Assessing Current and Potential Approaches in Multiple Myeloma: Updates From Madrid 2024

Raffaele Califano, MD - At the Frontline in ALK+ NSCLC: Practical Approaches to TKI Therapy

David Malka, MD, PhD - Providing Cutting-Edge Care for Cholangiocarcinoma: Transforming the Patient Journey

Carlo Antozzi, MD - From Helsinki: Expert Perspectives on the Next Generation of Clinical Evidence for FcRn Inhibitors in Myasthenia Gravis

Xenofon Baraliakos, MD, PhD / Philip Helliwell, MD, PhD - Can the Standard of Care Be Elevated in Spondyloarthropathies? Key Learnings From Rheumacensus Initiatives in PsA and axSpA

Milan J. Anadkat, MD - Supporting Patient-Centered Care in Generalized Pustular Psoriasis: Communications Strategies to Improve Shared Decision-Making

Xavier Montalban, MD, PhD - Multiple Sclerosis and Bruton's Tyrosine Kinase Inhibitors: Therapeutic Potential Beyond Biologics?

Lindsey Roeker, MD - Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents

Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics

Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient's Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy